Hbm Holdings Ltd
HKEX:2142
Intrinsic Value
HBM Holdings Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutics in the fields of immuno-oncology and immunology diseases. [ Read More ]
The intrinsic value of one Hbm Holdings Ltd stock under the Base Case scenario is 6.93 HKD. Compared to the current market price of 1.15 HKD, Hbm Holdings Ltd is Undervalued by 83%.
Valuation Backtest
Hbm Holdings Ltd
Run backtest to discover the historical profit from buying and selling Hbm Holdings Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Hbm Holdings Ltd
Current Assets | 210.2m |
Cash & Short-Term Investments | 140.3m |
Receivables | 52.3m |
Other Current Assets | 17.5m |
Non-Current Assets | 18.3m |
Long-Term Investments | 5.7m |
PP&E | 4.9m |
Intangibles | 7.7m |
Current Liabilities | 64.1m |
Accounts Payable | 15.4m |
Other Current Liabilities | 48.8m |
Non-Current Liabilities | 44.4m |
Long-Term Debt | 28.6m |
Other Non-Current Liabilities | 15.8m |
Earnings Waterfall
Hbm Holdings Ltd
Revenue
|
89.5m
USD
|
Cost of Revenue
|
-2m
USD
|
Gross Profit
|
87.5m
USD
|
Operating Expenses
|
-60.4m
USD
|
Operating Income
|
27.1m
USD
|
Other Expenses
|
-4.3m
USD
|
Net Income
|
22.8m
USD
|
Free Cash Flow Analysis
Hbm Holdings Ltd
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Hbm Holdings Ltd's profitability score is 44/100. The higher the profitability score, the more profitable the company is.
Score
Hbm Holdings Ltd's profitability score is 44/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Hbm Holdings Ltd's solvency score is 76/100. The higher the solvency score, the more solvent the company is.
Score
Hbm Holdings Ltd's solvency score is 76/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Hbm Holdings Ltd
According to Wall Street analysts, the average 1-year price target for Hbm Holdings Ltd is 1.72 HKD .
Shareholder Return
Price
Hbm Holdings Ltd
Average Annual Return | -31.27% |
Standard Deviation of Annual Returns | 25.58% |
Max Drawdown | -93% |
Market Capitalization | 883.7m HKD |
Shares Outstanding | 736 164 550 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
HBM Holdings Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutics in the fields of immuno-oncology and immunology diseases. The Company’s products include batoclimab, mainly used for immune thrombocytopenia (ITP), graves’ ophthalmopathy (GO), myasthenia gravis (MG), neuromyelitis optica spectrum disorder (NMOSD); and tanfanercept, mainly used for dry eye disease (DED). In addition, the Company researches and develops immuno-oncology portfolio, including internally developed next-generation immune-oncology assets targeting immune-desert, immune-excluded and inflamed tumors.
Contact
IPO
Employees
Officers
The intrinsic value of one Hbm Holdings Ltd stock under the Base Case scenario is 6.93 HKD.
Compared to the current market price of 1.15 HKD, Hbm Holdings Ltd is Undervalued by 83%.